Haffkine Bio-Pharma hopeful of Covaxin production in 8 months, targets 22.8 crore doses a year

The Dept of Biotechnology has given permission to HBOCL for producing Covaxin under Mission COVID Suraksha.

Maharashtra government undertaking, Haffkine Bio-Pharmaceutical Corporation Limited (HBPCL) is bucking up for mass production of Covaxin and will have capacity to produce over 22 crore doses of the COVID-19 vaccine every year once the requisite facilities are in place.


 

The Department of Biotechnology has given permission to the corporation for producing Covaxin under Mission Covid Suraksha. Covaxin has been developed by Bharat Biotech in collaboration with ICMR.


 

Sandeep Rathod, Managing Director of HBPCL, said that formalities of technology transfer from Bharat Biotech are being completed.


 

"We are completing formalities of technology transfer and they will be completed soon. We have signed the confidentiality clause with Bharat Biotech and the finalisation of MoU is under process," he said.


 

Rathod said bio-safety lab (BSL) for production of COVID vaccines is being established and work for establishing the facilities will take about eight months.


 

"We are hopeful that everything will be favourable and we will start production within our estimated time. Once the production starts, we will have a capacity for production of 2 crore doses every month. With that speed, we can work 11 months in a year and can produce 22.8 crore doses every year," he said.


 

The HBPCL official further said that they were getting required funds for the project.

India Scanner News Network

Leave a comment